During the last three months, 7 analysts shared their evaluations of Moderna (NASDAQ:MRNA), revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Analysts’ evaluations of 12-month price targets offer additional insights, showcasing an average target of $132.14, with a high estimate of $163.00 and a low estimate of $106.00. Marking an increase of 5.5%, the current average surpasses the previous average price target of $125.25. Decoding …